logo
logo

Inmune Bio, Inc. announced it raised $3.34 Million in an initial filing from an offering of $5 Million

Jul 13, 2017almost 8 years ago

Amount Raised

$3.34 Million

Round Type

seed

La Jolla

Company Information

Company

Inmune Bio, Inc.

Location

1224 PROSPECT STREET

La Jolla, California, United States

About

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB) clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19 complications (QuellorTM), cancer (INB03TM), Alzheimer's and Treatment Resistant Depression (XPro1595), and NASH (LIVNateTM). The Natural Killer Cell Priming Platform includes INKmuneTM aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.

FundzWatch™ Score

69
Medium Activity

Buyer Intent Analysis

Get personalized insights on buying likelihood

Related People